Allosteric drugs: Thinking outside the active-site box

Chemistry and Biology

Volumn 7, Issue 5, 2000, Pages

  Dedecker, Brian S ^a  

^a Harvard Inst Chem and Cell Biol   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034111186     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00115-0     Document Type: Review

References (21)

1. Zhang R.-g, Joachimiak A., Lawson C.L., Schevitz R.W., Otwinowski Z., Sigler P.B. The crystal structure of trp aporepressor at 1.8 Å shows how binding tryptophan enhances DNA affinity. Nature. 327:1987;591-597.
2. Monod J., Changeux J.-P., Jacob F. Allosteric proteins and cellular control systems. J. Mol. Biol. 6:1963;306-309.
3. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutation in human cancers. Science. 253:1991;49-53.
4. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
5. Kelley R., Yanofsky C. Mutational studies with the trp repressor of Escherichia coli support the helix-turn-helix model of repressor recognition of operator DNA. Proc. Natl Acad. Sci. USA. 82:1985;483-487.
6. Serrano L., Day A.G., Fersht A.R. Step-wise mutation of barnase to binase: a procedure for engineering increased stability of proteins and an experimental analysis of the evolution of protein stability. J. Mol. Biol. 233:1993;305-312.
7. Wells J.A. Additivity of mutational effects in proteins. Biochemistry. 29:1990;8509-8517.
8. Brachman R.K., Yu K., Eby Y., Pavletich N.P., Boeke J.D. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17:1998;1847-1859.
9. Nikolova P.V., Wong K.-B., DeDecker B., Henckel J., Fersht A.R. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19:2000;370-378.
10. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286:1999;2507-2510.
11. Bullock A.N., Fersht A.R.et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl Acad. Sci. USA. 94:1997;14338-14342.
12. Pennisi E. Bracing p53 for the war on cancer. Science. 286:1999;2431.
13. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:1990;671-680.
14. Bullock A.N., Henckel J., Fersht A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene. 19:2000;1245-1256.
15. Selivanova G., Wiman K.G.et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:1997;632-638.
16. Hupp T.R., Sparks A., Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 83:1995;237-245.
17. Friedlander P., Legros Y., Soussi T., Prives C. Regulation of mutant p53 temperature-sensitive DNA binding. J. Biol. Chem. 271:1996;25468-25478.
18. McMillan K., Devlin J.J.et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl Acad. Sci. USA. 97:2000;1506-1511.
19. Lefstin J.A., Yamamoto K.R. Allosteric effects of DNA on transcriptional regulators. Nature. 392:1998;885-888.
20. Kay L.E. Protein dynamics from NMR. Nat. Struct. Biol. 5:1998;145-152.
21. Carson M. Ribbons 2.0. J. Appl. Crystallogr. 24:1991;958-961.